Adial pharmaceuticals, inc.ADIL.US Overview

US StockHealthcare

(No presentation for ADIL)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ADIL Overall Performance

ADIL AI Analysis & Strategy

ADIL Recent Performance

-4.24%

Adial pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ADIL PowerScanner

ADIL Key Information

ADIL Valuation Metrics

ADIL Earnings Table

ADIL Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.